Enliven Therapeutics Inc. (ELVN)
NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ELVN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.03B
- EPS (TTM)
- -$1.63
- Dividend yield
- None
- 52-week range
- 14.79 – 62.32
- Day range
- 41.04 – 42.30
- Volume / Avg
- 1.46M / 1.11M
- Beta
- —
- Shares outstanding
- 73.27M
- Next earnings
- Nov 11, 2026
52-week range
ELVN stock today
Enliven Therapeutics (ELVN) closed at $41.36 on Oct 7, down 2.43% (-$1.03), versus the S&P 500's 0.22% decline. Shares are 33.6% below their 52-week high of $62.32, set on Aug 5, 2026 and 179.7% above the 52-week low of $14.79, in the middle of the past year's range. ELVN is up 168.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 105.7%.
Enliven Therapeutics has posted a net loss over the last twelve months (EPS of -$1.63), so its P/E ratio is not meaningful. Enliven Therapeutics's next earnings report is expected on Nov 11, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Enliven Therapeutics
Company profileEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Richard A. Fair M.B.A.
- Headquarters
- Boulder, CO
- Employees
- 67
- IPO year
- 2020
- Website
- enliventherapeutics.com
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$73.67+78.12%
- Strong buy 3
- Buy 11
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 11, 2026
Enliven Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARQTArcutis Biotherapeutics Inc. | 24.17 | +1.05% | $3.04B | vs ELVN |
| DYNDyne Therapeutics Inc. | 15.97 | +3.70% | $2.98B | vs ELVN |
| RCUSArcus Biosciences Inc. | 24.52 | +0.99% | $3.08B | vs ELVN |
| ZLABZai Lab Limited ADR | 25.31 | -1.06% | $2.84B | vs ELVN |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 7.43 | -5.35% | $2.75B | vs ELVN |
| PGENPrecigen Inc. | 7.54 | -0.13% | $2.70B | vs ELVN |
| ACADACADIA Pharmaceuticals Inc. | 19.65 | -0.46% | $3.39B | vs ELVN |
| AMLXAmylyx Pharmaceuticals Inc. | 27.43 | -2.18% | $3.44B | vs ELVN |
Indexes, lists and sector
Enliven Therapeutics stock FAQ
What is Enliven Therapeutics's stock price today?
ELVN last traded at $41.36 as of Oct 7, 4:00 PM EDT, down 2.43% on the day. Prices are delayed at least 15 minutes.
When is Enliven Therapeutics's next earnings date?
Enliven Therapeutics is expected to report earnings on Wednesday, November 11, 2026.
Who is Enliven Therapeutics's CEO?
Mr. Richard A. Fair M.B.A. is the chief executive officer of Enliven Therapeutics Inc., which has about 67 employees.
What is the ELVN 52-week high?
The 52-week high for ELVN is $62.32 and the 52-week low is $14.79. The stock is currently 33.6% below its high.